Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890370 | 0.87 | ACHE (0.55) | BCHEALDH1A1ACHECHRNA7MAOB | |
| SCHEMBL12890021 | 0.85 | BCHE (0.69) | BCHEACHECHRNA7MAOBCCR3 | |
| SCHEMBL27544341 | 0.83 | BCHE (0.66) | BCHEACHECHRNA7MAOBCCR3 | |
| SCHEMBL5809206 | 0.80 | FAAH (0.73) | BCHEACHECHRNA7MAOBFAAH | |
| SCHEMBL27751851 | 0.79 | KMT2A (0.68) | ALDH1A1CHRNA7 | |
| SCHEMBL16800289 | 0.79 | ALDH1A1 (0.66) | ALDH1A1FAAH | |
| SCHEMBL27858010 | 0.79 | BCHE (0.76) | BCHEACHECHRNA7MAOBCCR3 | |
| SCHEMBL2576912 | 0.79 | FAAH (0.76) | BCHEACHECHRNA7MAOBFAAH | |
| SCHEMBL20088734 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CHRNA7RAB9A | |
| SCHEMBL28171857 | 0.77 | BCHE (0.70) | BCHEACHEMAOBCCR3CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | BCHE 3719/4885ALDH1A1 2989/4885ACHE 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.